322 related articles for article (PubMed ID: 142131)
21. A review of the basic mechanisms of fibrinogen to fibrin conversion and of fibrinolysis: intravascular coagulation versus primary fibrinolysis.
Colick JA; Fisher LM
Va Med Mon (1918); 1970 May; 97(5):310-4 passimass. PubMed ID: 4276992
[No Abstract] [Full Text] [Related]
22. Electrophoretic demonstration of high molecular weight fibrin degradation products persisting in chronic subdural hematomas.
Toyosawa M; Kashiwagi S; Pei W; Fujisawa H; Ito H; Nakamura K
Electrophoresis; 1997 Jan; 18(1):118-21. PubMed ID: 9059832
[TBL] [Abstract][Full Text] [Related]
23. [Effect of fibrin-fibrinogenolysis on the determination of the fibrinogen content and fibrin-fibrinogen degradation products (FDP) by means of the fibrin polymerization time (FPT test)].
Vorlová Z; Dyr IE
Folia Haematol Int Mag Klin Morphol Blutforsch; 1979; 106(5-6):967-70. PubMed ID: 94893
[No Abstract] [Full Text] [Related]
24. Epidemic hemorrhagic fever. The mechanism of coagulation and fibrinolysis.
Xiang LB; Zhang ZY; Chen JM; Xiang JM; Cosgriff TM
Chin Med J (Engl); 1990 May; 103(5):391-5. PubMed ID: 1975230
[TBL] [Abstract][Full Text] [Related]
25. [Monoclonal antibodies against fibrinogen and fibrin and against their proteolytic degradation products].
Dyr JE; Cajthamlová H; Suttnar J
Cas Lek Cesk; 1990 Oct; 129(43):1349-51. PubMed ID: 2249231
[TBL] [Abstract][Full Text] [Related]
26. The hematologic consequences of thrombolytic therapy.
Fletcher AP; Alkjaersig NK
Prog Hematol; 1986; 14():183-200. PubMed ID: 2935903
[No Abstract] [Full Text] [Related]
27. [Fibrinolysis].
Levy G; Michault A; Jamet M
Ann Anesthesiol Fr; 1978; 19(8):703-8. PubMed ID: 31114
[TBL] [Abstract][Full Text] [Related]
28. Comparison of ethanol and protamine tests in demonstration of soluble fibrin and early products of fibrin degradation.
Konttinen YP; Kemppainen L; Turunen O
Thromb Diath Haemorrh; 1972 Dec; 28(3):342-50. PubMed ID: 4675265
[No Abstract] [Full Text] [Related]
29. Disseminated intravascular coagulation and the balance between blood coagulation and fibrinolysis.
Astrup T; Jespersen J
Folia Haematol Int Mag Klin Morphol Blutforsch; 1984; 111(4):407-15. PubMed ID: 6083904
[TBL] [Abstract][Full Text] [Related]
30. [Comparative study of various rapid methods of determining fibrinogen transformation products in the diagnosis of intravascular coagulation and fibrinolysis].
Lychev VG; Momot AP; Cherkashin GV
Ter Arkh; 1984; 56(6):106-9. PubMed ID: 6474366
[TBL] [Abstract][Full Text] [Related]
31. Characterization of fibrin/fibrinogen degradation products reagents and their utility in critical care patients with enhanced fibrinolysis.
Kumano O; Ieko M; Komiyama Y; Naito S; Yoshida M; Takahashi N; Ohmura K; Hayakawa M
Int J Lab Hematol; 2021 Aug; 43(4):813-820. PubMed ID: 33301236
[TBL] [Abstract][Full Text] [Related]
32. A rapid method for the semiquantitative determination of fibrinogen and fibrinogen degradation products (FDP) in defibrination syndrome.
Sas G; Jákó J; Domán J; László C; Pádár J
Thromb Diath Haemorrh; 1971 Jun; 25(3):555-65. PubMed ID: 4254505
[No Abstract] [Full Text] [Related]
33. Progress in the measurement of circulating fibrinogen derivatives.
Wilner GD
Prog Clin Pathol; 1984; 9():15-45. PubMed ID: 6229812
[No Abstract] [Full Text] [Related]
34. [Proceedings: 72. Fibrinogen-fibrin degradation products (FDP) (author's transl)].
Matsuda T
Nihon Seirigaku Zasshi; 1973; 35(8):411-2. PubMed ID: 4274786
[No Abstract] [Full Text] [Related]
35. [Critical evaluation of new methods for studying fibrin degradation products].
Prisco D
Recenti Prog Med; 1989 May; 80(5):263-7. PubMed ID: 2669062
[TBL] [Abstract][Full Text] [Related]
36. Proteolytic degradation products from fibrinogen and fibrin with special respect to non-covalently associated complexes. Influence of fibrin crosslinking. Lysability and other properties.
Feddersen C
Scand J Clin Lab Invest Suppl; 1983; 166():1-60. PubMed ID: 6226084
[No Abstract] [Full Text] [Related]
37. [Fibrinolysis activities and factor XIII in the neonatal period. 1. Fibrinolysis activity and fibrin degradation products in the neonatal period].
Yamada Z
Nihon Shonika Gakkai Zasshi; 1971 Apr; 75(4):294-6. PubMed ID: 4252802
[No Abstract] [Full Text] [Related]
38. [Relation between fibrin/fibrinogen degradation products in malignant fluids and the fibrinolytic activity of the peritoneum].
Takahashi M; Yoshida K; Kano K; Machida T; Nakamura Y; Miura Y; Miura N; Kanno S
Gan No Rinsho; 1986 Dec; 32(15):1945-9. PubMed ID: 3806965
[TBL] [Abstract][Full Text] [Related]
39. [A comprehensive laboratory evaluation of changes in the fibrinogen molecule in the diagnosis of acquired coagulopathy conditions].
Siatkovskiĭ VA; Azarova LA; Vasilenko PL
Lab Delo; 1989; (8):45-8. PubMed ID: 2477628
[TBL] [Abstract][Full Text] [Related]
40. [Fluctuation of plasma levels of fibrinogen degradation products, fibrin degradation products and total fibrin/fibrinogen degradation products in patients with DIC].
Isogai N; Kuroso K; Fujimaki M; Yorifuji H; Fukutake K
Rinsho Byori; 1993 Dec; 41(12):1349-52. PubMed ID: 8295346
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
